Table 4 Univariate Cox regression analysis of the impact of the lncRNA signature and other clinicopathological features on OS in the three NSCLC patient cohorts
Parameters | Training cohort | Validation cohort | Independent cohort | |||
|---|---|---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
Signature | ||||||
 (High vs low) | 3.20 (0.58–1.65) | < 0.001 | 2.84 (1.59–5.07) | < 0.001 | 2.84 (1.59–5.07) | 0.009 |
Age | ||||||
 (≥ 60 vs < 60) | 1.24 (0.73–2.09) | 0.417 | 1.13 (0.67–1.91) | 0.330 | 0.88 (0.36–2.13) | 0.782 |
Gender | ||||||
 (Male vs female) | 0.86 (0.48–1.52) | 0.619 | 1.24 (0.63–2.41) | 0.050 | 0.98 (0.37–2.57) | 0.978 |
TNM stages | ||||||
 (III vs II vs I) | 1.67 (1.28–2.19) | < 0.001 | 1.70 (1.30–2.23) | 0.001 | 1.74 (1.04–2.89) | 0.031 |
Histological type | ||||||
 (ADC vs SCC) | 1.30 (0.74–2.29) | 0.346 | 1.39 (0.82–2.36) | 0.589 | 0.53 (0.15–1.83) | 0.320 |
Tumor size | ||||||
 (≥ 5 cm vs < 5 cm) | 1.17 (0.69–1.98) | 0.545 | 1.15 (0.68–1.95) | 0.017 | 3.00 (1.00–9.00) | 0.048 |
Differentiation | ||||||
 (Poor vs well/mod) | 0.98 (0.58–1.65) | 0.951 | 1.43 (0.85–2.42) | 0.079 | 1.80 (0.74–4.32) | 0.188 |
Lymph metastasis | ||||||
 (Yes vs no) | 1.44 (0.86–2.43) | 0.163 | 0.73 (0.43–1.24) | 0.025 | 1.38 (0.46–4.14) | 0.561 |
Smoking history | ||||||
 (Yes vs no) | 0.91 (0.54–1.54) | 0.736 | 1.63 (0.92–2.91) | 0.024 | 1.11 (0.46–2.68) | 0.812 |
Fam. cancer hist. | ||||||
 (Yes vs no) | 1.04 (0.52–2.06) | 0.899 | 1.18 (0.58–2.42) | 0.580 | 0.47 (2.97–7.64) | 0.618 |